



Scientific Posters

ARV-based Prevention

- P001 Progress in HIV cascade in Russia from 2011 to 2019**
Pokrovskaya, A; Popova, A; Suvorova, Z; Dementieva, L; Pokrovsky, V (Moscow, Russian Federation)*
- P002 Side effects of antiretroviral therapy and their association with adherence among postpartum Malawian women**
Whittaker, M; Woodd, S; van Lettow, M; van Oosterhout, J; Tippett Barr, B; Kim, E; Schouten, E; Auld, A; Kalua, T; Jahn, A; Landes, M (London, UK)*
- P003 Maintaining medical care for PrEP users via home sampling during the COVID-19 shutdown in Switzerland: Checkpoint@home**
Hampel, B; Drescher, S; Baumann, B; Borso, D; Hijatzi, L; Fehr, J (Zurich, Switzerland)*
- P004 Disclosure of PrEP status and its association with online sexual networking among men who have sex with men in Hong Kong**
Lau, Y; Wong, N; Lee, S (Hong Kong, Hong Kong)*
- P005 Cork University Hospital clinical audit: the management of pregnancies in HIV-positive women and the safety and efficacy of ART during pregnancy**
Meek, J; Rizzo, G; Murphy, E (Cork, Ireland)*

Treatment Strategies: New Treatments and Targets

- O414 Safety and efficacy of cabotegravir + rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results**
D'Amico, R; Orkin, C; Bernal Morell, E; Tan, D; Katner, H; Singh, Y; Stellbrink, H; Belonosova, E; DeMoor, R; Griffith, S; Thiagarajah, S; Van Solingen-Ristea, R; Crauwels, H; Ford, S; Patel, P; Cutrell, A; Smith, K; Vandermeulen, K; Margolis, D; St. Clair, M; Spreen, W (London, UK)*
- O416 Single doses of MK-8507, a novel HIV-1 NNRTI, reduced HIV viral load for at least a week**
Ankrom, W; Schuermann, D; Jackson Rudd, D; Schaeffer, A; De Lepeleire, I; Friedman, E; Robberechts, M; Zhang, S; Keicher, C; Hofmann, J; Stoch, A; Iwamoto, M (West Point, PA, USA)*
- O442 A combination of viral and participant factors influence virologic outcome to long-acting cabotegravir and rilpivirine: multivariable and baseline factor analyses across ATLAS, FLAIR, and ATLAS-2M phase III studies**
Margolis, D; Schapiro, J; Perno, C; Kuritzkes, D; Quercia, R; Patel, P; Polli, J; Cutrell, A; Dorey, D; Wang, Y; Wu, S; van Eygen, V; Crauwels, H; Ford, S; Baker, M; Talarico, C; St. Clair, M; Jeffrey, J; White, C; Vanveggel, S; Van Solingen-Ristea, R; Vandermeulen, K; Spreen, W; van Lunzen, J (Research Triangle Park, NC, USA)*
- P006 Cabotegravir + rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results**
Swindells, S; Lutz, T; Van Zyl, L; Porteiro, N; Benn, P; Huang, J; Harrington, C; Hove, K; Ford, S; Talarico, C; Chounta, V; Crauwels, H; Van Solingen-Ristea, R; Vanveggel, S; Margolis, D; Smith, K; Vandermeulen, K; Spreen, W (Omaha, NE, USA)*
- P007 Multicenter, open-label, post-authorization safety study (PASS) of elsulfavirine (Elpida®) used in the first-line therapy for HIV-1 infected patients added to standard ART (NNRTI + two NRTIs)**
Yakubova, E; Kravchenko, A; Shimonova, T; Bessarab, T; Sizova, N; Stepanova, E; Pokrovskaya, A; Kuimova, U; Kuznetsova, A; Radzikhovskaya, M; Pozdnyakova, L; Ulyanova, Y; Gusev, D; Yakovlev, A; Kovelonov, A; Inozemtseva, E; Baranovsky, S; Arsenko, R; Remeeva, J; Corritori, S; Savchuk, N; Dukes, I; Weichert, A; Richman, D; Murphy, R (Chicago, IL, USA)*



Scientific Posters

Treatment Strategies: New Treatments and Targets (continued)

- P008** **Social, psychological, and treatment-related challenges of a new HIV diagnosis in old age**
Spinelli, F; Okoli, C; de los Rios, P; Nwokolo, N; Short, D (Research Triangle Park, NC, USA)*
- P009** **HIV cure trials acceptability, representations and ethical issues among patients living with HIV: a qualitative study**
Lesage, S; Gilles, I; Storari, C; Peytremann Bridevaux, I; Barbieux, C; Vittoz, L; Calmy, A (Lausanne, Switzerland)*
- P010** **Efficacy and safety of dolutegravir in treatment-naive people living with HIV-1 stratified by age: meta-analysis of 48-week results from ARIA, FLAMINGO, SINGLE, and SPRING-2**
Spinelli, F; Prakash, M; Slater, J; van der Kolk, M; Bassani, N; Grove, R; Wynne, B; van Wyk, J; Clark, A (Research Triangle Park, NC, USA)*
- P011** **Comparability of 48-week efficacy and safety of cabotegravir + rilpivirine long-acting every 8 weeks to standard of care in suppressed HIV-1-infected patients**
Chounta, V; Snedecor, S; Wu, S; Van de Velde, N (Brentford, UK)*
- P012** **Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)**
Chounta, V; Wu, S; Upadhyay, O; Griffith, S; Harrington, C; Orkin, C; Swindells, S; Spreen, W; Margolis, D (Brentford, UK)*
- P013** **Experience from a real-life cohort: outcome of 984 HIV infected patients treated with bictegravir/emtricitabine/tenofovir alafenamide in Hospital Clinic, Barcelona**
Rojas Liévano, J; Berrocal, L; Inciarte, A; De la Mora, L; González-Cordón, A; Martínez-Rebollar, M; Laguno, M; Torres, B; Ugarte, A; Chivite, I; Leal, L; Ambrosioni, J; Blanco, J; Martínez Chamorro, E; Mallolas, J (Barcelona, Spain)*
- P014** **Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and physicians in western Europe**
Akinwunmi, B; Buchenberger, D; Scherzer, J; Bode, M; Rizzini, P; Vecchio, F; Roustand, L; Nachbaur, G; Finkielsztej, L; Chounta, V; van de Velde, N (Brentford, UK)*
- P015** **Long-acting treatments: people's expectations and attending physicians' preparedness. Are we ready to manage it?**
Celesia, M; Ceccarelli, M; Trezzi, M; Tzannis, A; Errico, M; Cinque, P; Focà, E; Ripamonti, D; Martini, S; Nozza, S; Gervasoni, C; Dentone, C; Cenderello, G; Calcagno, A; Orofino, G; Cattelan, A; Tacconelli, E; Vichi, F; Saracino, A; Lo Caputo, S; De Socio, G; Guadagnino, G; Parruti, G; Cingolani, A; Borderi, M; Mussini, C; D'ettorre, G; Maggi, P; Quirino, T; Madeddu, G; Capetti, A; Di Biagio, A; Cacopardo, B; Celesia, B (Milano, Italy)*
- P016** **What about me? The unmet needs of men who have sex with women and differences in HIV treatment experiences, perceptions, and behaviors by gender and sexual orientation in 25 countries**
Okoli, C; Van de Velde, N; Brough, G; Hardy, W; Corbelli, G; Allan, B; Muchenje, M; Castellanos, E; Young, B; Eremin, A; Ramothwala, P; de los Rios, P (Brentford, UK)*



Scientific Posters

Treatment Strategies: Target Populations

- P017 Outcomes for women receiving long-acting cabotegravir + rilpivirine monthly and every 2 months: ATLAS-2M study Week 48 results**
Benn, P; Quercia, R; Hudson, K; Wang, Y; Chounta, V; Talarico, C; Ford, S; Cutrell, A; Margolis, D; Van Solingen-Ristea, R; Vanveggel, S; Van Eygen, V; Polli, J; de Ruiter, A; Smith, K; Spreen, W (Brentford, UK)*
- P018 Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection: 3-year results from the GEMINI studies**
Cahn, P; Sierra-Madero, J; Arribas, J; Antinori, A; Ortiz, R; Clarke, A; Hung, C; Rockstroh, J; Girard, P; Sievers, J; Man, C; Urbaityte, R; Underwood, M; Pappa, K; Smith, K; Gartland, M; Aboud, M; van Wyk, J; Wynne, B (Buenos Aires, Argentina)*
- P019 Clinical significance of gp120 polymorphisms, temsavir IC50FC, and HIV-1 subtype in BRIGHT**
Gartland, M; Ackerman, P; Mannino, F; Garside, L; Clark, A; Pierce, A; Krystal, M; Llamoso, C; Lataillade, M (Research Triangle Park, NC, USA)*
- P020 Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed PLWH: the STAT study**
Rolle, C; Berhe, M; Singh, T; Ortiz, R; Wurapa, A; Ramgopal, M; Leone, P; Matthews, J; Dalessandro, M; Underwood, M; Angelis, K; Wynne, B; Merrill, D; Nguyen, C; van Wyk, J (Orlando, FL, USA)*
- P021 Fostemsavir exposure-response relationships in treatment-experienced HIV patients**
Parasrampuria, R; Goyal, N; Moore, K; Ackerman, P; Llamoso, C; Barker, K; Magee, M (Collegeville, PA, USA)*
- P022 Model-based approach of dose selection and optimal pharmacokinetics sampling of fostemsavir for pediatric patients with multidrug resistant HIV-1 infection**
Thakkar, N; Magee, M; Moore, K; Ackerman, P; Chabria, S; Llamoso, C; Goyal, N (Upper Providence, PA, USA)*
- P023 Virological, immunological response and safety of initial antiretroviral treatment in HIV late presenters in HIV Spanish National Cohort**
Bisbal, O; Rava, M; Domínguez-Domínguez, L; Jarrín, I; Iribarren, J; Gutierrez, F; García Rosado, D; Górgolas, M; Peraire, J; Poveda, E; Rubio, R; Moreno, S (Madrid, Spain)*
- P024 HIV-DNA decrease during treatment in primary HIV-1 infection: a randomised clinical trial with three different drug regimens**
Nozza, S; Gabrielli, A; Bernasconi, D; Marchetti, G; Calcagno, A; Ripamonti, D; Antinori, A; Squillace, N; Cauda, R; Parisi, M; Muscatello, A; Bandera, A; Tambussi, G; Rusconi, S (Milan, Italy)*
- P025 Clinical profile, antiretroviral drug exposure and virological status of perinatally HIV-infected adolescents transferred from paediatric to adult HIV care: 20 years of experience in a public hospital in Buenos Aires, Argentina**
Cordova, E; Arazi Caillaud, S; Rodriguez, C (Buenos Aires, Argentina)*
- P027 Efficacy and durability of raltegravir-based dual therapy**
Cassol, C; Dolci, G; Emiliozzi, A; Gennari, W; Bruzzone, B; Vicenti, I; Micheli, V; Borghi, V; Callegaro, A; Monno, L; Rusconi, S; Laghetti, P; Lombardi, F; Zazzi, M; Fabbiani, M (Siena, Italy)*



Scientific Posters

Treatment Strategies: Target Populations (continued)

- P028** **Effect of online education on physician knowledge and confidence for the immunological drivers of depletion and recovery for CD4 T cells and implications of non-response in HIV-positive individuals**
*Duffey, J**; Voorn, S; Sutton, R (Matlock, UK)

Treatment Strategies: Adherence

- P029** **Impact of adherence on viral suppression with bicitgravir and dolutegravir (DTG) containing triple therapy in clinical practice**
*Sax, P**; Althoff, K; Eron, J; Radtchenko, J; Diaz-Cuervo, H; Mounzer, K; Ramgopal, M; Santiago, S; Elion, R (Boston, MA, USA)
- P030** **Cost-utility analysis of long-acting cabotegravir + rilpivirine for the treatment of HIV infection in the United Kingdom**
*Parker, B; Chounta, V; Gait, C; Hayward, O; Hunjan, M; Schroeder, M; Jacob, I; Van de Velde, N** (London, UK)
- P031** **Beyond viral load: exploring mediating factors for the gap in optimal self-rated health by adherence status among older adults living with HIV**
*Spinelli, F**; Okoli, C; de los Rios, P; Nwokolo, N; Short, D (Research Triangle Park, NC, USA)
- P032** **Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US**
*Sutton, S**; Wang, X; Diaz-Cuervo, H; Magagnoli, J (Columbia, SC, USA)
- P033** **Self-care and involvement in managed care among people living with HIV in Europe**
*Okoli, C**; Corbelli, G; Brough, G; Van de Velde, N; de los Rios, P (Brentford, UK)
- P034** **Role of patient's pathway on HIV service organisation and adherence to treatment**
*Lopatina, Y**; Momotyuk, G; Zakowicz, A (Kyiv, Ukraine)
- P035** **The relationship between the quality of care perceived by the patient and adherence to antiretroviral treatment**
*Gimeno-García, A**; Montero-Hernández, C; Franco-Moreno, A; Arponen, S; García-Carrasco, É; Alejos, B; Corps-Fernández, D; Varillas-Delgado, D; Galindo-Jara, P; García-Navarro, M (Torrejón de Ardoz, Spain)

Treatment Strategies: Simplification and Switch Studies

- O441** **Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study)**
*van Wyk, J; Ajana, F; Bisshop, F; De Wit, S**; Osiyemi, O; Portilla, J; Routy, J; Wyen, C; Ait-Khaled, M; Nascimento, M; Pappa, K; Wang, R; Wright, J; Wynne, B; Aboud, M; Smith, K (Brussels, Belgium)
- P036** **Long-term follow-up after a switch to bicitgravir, emtricitabine, tenofovir alafenamide, from a boosted protease inhibitor-based regimen**
*Rockstroh, J**; Molina, J; Post, F; Fox, J; Koenig, E; Daar, E; DeJesus, E; Ruane, P; Crofoot, G; Oguchi, G; Creticos, C; Liu, A; Andreatta, K; Graham, H; Brainard, D; Martin, H (Bonn, Germany)



Scientific Posters

Treatment Strategies: Simplification and Switch Studies (continued)

- P037** Long-term treatment efficacy and safety following switch to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF): Week 144 results of the DRIVE-SHIFT trial
Kumar, P; Johnson, M; Molina, J; Rizzardini, G; Cahn, P; Bickel, M; Wan, H; Morais, C; Sklar, P; Greaves, W (Washington, DC, USA)*
- P038** Switching to bicitegravir/emtricitabine/tenofovir alafenamide in adults aged >65 years or older: Week 72 results from an international, phase IIIb, open-label trial
Maggiolo, F; Rizzardini, G; Molina, J; Pulido, F; De Wit, S; Vandekerckhove, L; Berenguer, J; D'Antoni, M; Blair, C; Chuck, S; Piontkowsky, D; Martin, H; Haubrich, R; McNicholl, I; Gallant, J (Bergamo, Italy)*
- P039** 12-months outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected patients: real-world data from the German JUNGLE cohort
Noe, S; Ummard-Berger, K; Hillenbrand, H; Beer, D; Wyen, C; Pauli, R; Postel, N; Dymek, K; Westermayer, B; Scherzer, J (Munich, Germany)*
- P040** Early discontinuation of ABC/3TC/DTG and BIC/TAF/FTC single-tablet regimens: a real-life multicentre cohort study
Lagi, F; Botta, A; Arturo, C; Chiara, P; Fabbiani, M; Di Giambenedetto, S; Borghi, V; Mussini, C; Bartoloni, A; Gaetana, S (Firenze, Italy)*
- P041** Real-world experience using bicitegravir/emtricitabine/tenofovir-alafenamide (B/F/TAF) in a Scottish HIV cohort
Proud, E; Murphy, C (Glasgow, UK)*
- P042** Does tuberculosis coinfection increase the risk of being on second-line antiretroviral therapy in Tanzania?
Mollel, E; Masanja, R; Todd, J; Msuya, S; Mahande, M (Kilimanjaro, Tanzania)*
- P043** Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in an observational Italian cohort: interim analysis of DIAMANTE (TMC114FD1HTX4011) study
Antinori, A; Vergori, A; Rizzardini, G; Ripamonti, D; Esposito, V; Rusconi, S; Manzillo, E; Orofino, G; Andreoni, M; Lazzarin, A; Madeddu, G; Cascio, A; Uglietti, A; Termini, R; Portaro, M; Mancusi, D (Cologno Monzese, Italy)*
- P044** Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) + lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany
Postel, N; Schneeweiss, S; Wyen, C; Schabaz, F; Degen, O; Weinberg, G; Sabranski, M; Ummard-Berger, K; Dymek, K; Westermayer, B; Scherzer, J (Munich, Germany)*
- P045** Dual HIV treatment in experienced HIV patients
Battagin, G; Parisi, S; Giordani, M; Paolo, F; Mascarello, M; Del Punta, V; Luise, D; Timillero, L; Manfrin, V (Vicenza, Italy)*



Scientific Posters

Treatment Strategies: Other

- O112 Weight gain plateaus at 24-months follow-up for ART-experienced patients that switched to dolutegravir in a Nigerian early adopter cohort**
Campbell, J; Abudjore, O; Amamilo, I; Harwell, J; Middlecote, C; Conroy, J; Eigege, W; Otubu, N; Jiboye, J; Anomnachi, L; Lufadeju, F; Amole, C; Wiwa, O; Agbaji, O; Anweh, D; Akanmu, S (Boston, MA, USA)*
- O415 Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks**
Molina, J; Yazdanpanah, Y; Afani Saud, A; Bettacchi, C; Chahin Anania, C; DeJesus, E; Klopfer, S; Grandhi, A; Eves, K; Hepler, D; Robertson, M; Hwang, C; Hanna, G; Correll, T (Paris, France)*
- P046 Starting or switching to bicitgravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the global BICSTaR study**
Spinner, C; Stoehr, A; Wong, A; de Wet, J; Zeggagh, J; Hocqueloux, L; van Welzen, B; Heinzkill, M; Sahali, S; Torres Cornejo, A; Ramroth, H; Haubrich, R; Thorpe, D; Kim, C (Munich, Germany)*
- P047 Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naïve adults with HIV-1**
Orkin, C; Molina, J; Yazdanpanah, Y; Chahin Anania, C; DeJesus, E; Eron, J; Klopfer, S; Grandhi, A; Xu, J; Eves, K; Hepler, D; Robertson, M; Hwang, C; Hanna, G; Correll, T (London, UK)*
- P048 Renal safety through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naïve adults with HIV-1**
Post, F; McMullan, C; DiPerri, G; Molina, J; Klopfer, S; Grandhi, A; Eves, K; Hepler, D; Hwang, C; Correll, T (London, UK)*
- P049 The occurrence of hypersensitivity reaction and hepatotoxicity in individuals receiving integrase strand transfer inhibitors: results from the EuroSIDA study**
Pelchen-Matthews, A; Larsen, J; Shepherd, L; Begovac, J; Pedersen, K; Curtis, L; De Wit, S; Horban, A; Jablonowska, E; Johnson, M; Khromova, I; Lusso, M; Nielsen, L; Ridolfo, A; Schmied, B; Stephan, C; Yust, I; Vannappagari, V; Roen, A; Raben, D; Kirk, O; Peters, L; Mocroft, A (London, UK)*
- P050 Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+ patients over 24 months - Results from the German TAFNES cohort study**
Stellbrink, H; Scholten, S; Hillenbrand, H; Knechten, H; Jessen, H; Schreiber, S; Goerner, K; Haubrich, R; Heinzkill, M (Hamburg, Germany)*
- P051 Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain**
Ruiz Alguero, M; Alejos, B; García Yubero, C; Riera, M; Iribarren, J; Asensi, V; Pasquau, F; Galera, C; Jarrín, I; Suárez-García, I (Madrid, Spain)*
- P052 Systematic review of patient-reported outcome measures (PROMs) used in clinical trials of HIV-infected adults on combination antiretroviral therapy (cART)**
Normandin, A; Mate, K; Houlding, E; Engler, K; Cox, J; Kronfli, N; Lessard, D; Lebouché, B (Montreal, Canada)*
- P053 Patient-reported outcomes after one year of routine clinical practice with bicitgravir/emtricitabine/tenofovir alafenamide in PLWH: the BICSTaR cohort**
Knechten, H; Stephan, C; Waizmann, M; Brunetta, J; Trottier, B; Bonnet, F; Duvivier, C; van Welzen, B; Mack, F; Tossonian, H; Thorpe, D; Torres Cornejo, A; Marongiu, A; Curbelo, R (Aachen, Germany)*



Scientific Posters

Treatment Strategies: Other (continued)

- P054 Narrative medicine as PROs to understand living with HIV from patients' experiences: TMC114FD1HTX4011 - DIAMANTE study**
Antinori, A; Vergori, A; Esposito, V; Carleo, M; Andreoni, M; Malagnino, V; Rusconi, S; Castelli, F; Focà, E; Manzillo, E; Pizzella, T; Cappuccio, A; Reale, L; Fiorencis, A; Marini, M; Portaro, M; Mancusi, D; Termini, R; Uglietti, A (Rome, Italy)*
- P055 Perceptions of HIV-infected men who have sex with men as regards functional cure of HIV infection**
Kwan, T; Chan, C; Wong, N; Lee, S (Shatin, Hong Kong)*
- P056 Durability of F/TAF in a large cohort of PLWH seen for care in Italy**
Vergori, A; Cozzi Lepri, A; Gianotti, N; Calcagno, A; Guaraldi, G; Orofino, G; Moioli, M; Gentile, I; Loredana, S; Cicalini, S; d'Arminio Monforte, A; Antinori, A (Rome, Italy)*
- P057 Improving methods for patient-reported outcome (PRO) analyses in observational HIV studies**
Williams, L; Marongiu, A; Reilly, G; Heinzkill, M; Haubrich, R; Castles, R; Filippidis, F; Ramroth, H (London, UK)*
- P058 Factors associated with quality of sexual life among women with HIV and HCV**
Rodriguez, S; Huntingdon, B; Juraskova, I; Preau, M; Etemadi, F; Galano, E; Carrieri, P; Bessonneau, P; Chassany, O; Duracinsky, M; Fofana Dara, A (Paris, France)*

Opportunistic Infections

- P059 Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes**
Savchenko, M; Panteleev, A (Saint-Petersburg, Russian Federation)*
- P060 Progressive multifocal leukoencephalopathy, still a challenge in the combined antiretroviral therapy era**
Ianache, I; Olaru, A; Radoi, R; Nica, M; Tardei, G; Ene, L; Oprea, C (Bucharest, Romania)*

Co-morbidities and Complications of Disease and/or Treatment: Ageing

- P061 Increased levels of immune activation and exhaustion in vertically HIV-1 infected young adults**
Tarancón-Díez, L; Carrasco, I; Vázquez-Alejo, E; Jiménez de Ory, S; Sainz, T; Apilanez, M; Rojo, P; Guillén, S; Ramos, J; Muñoz-Fernández, M; Navarro, M (Madrid, Spain)*
- P062 Prevalence of pain in women living with HIV aged 45-60: associated factors and impact on patient-reported outcomes**
Sabin, C; Okhai, H; Dhairyawan, R; Haag, K; Burns, F; Gilson, R; Sherr, L; Tariq, S (London, UK)*
- P063 Impact of baseline comorbidities on ART persistence and effectiveness in PLWH receiving F/TAF-based regimens: final 24-month results from the German TAFNES cohort study**
Scholten, S; Hillenbrand, H; Postel, N; Knechten, H; Pauli, R; Jessen, H; Emmerich, C; Pehlivan, C; Albuquerque, B; Haubrich, R; Stellbrink, H (Köln, Germany)*
- P064 Frailty of Greek PLWHIV in association with clinical markers and psychological factors: preliminary results of a nationwide study**
Tsakona, D; Kochelli, A; Chini, M; Meliou, M; Psychogiou, M; Basoulis, D; Panagopoulos, P; Petrakis, V; Karamanidou, C (Thessaloniki, Greece)*



Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Cardiovascular

- P065** **The association of incidental coronary calcification and imaging covariates in people living with HIV. Results from the Liverpool Multiparametric Imaging Collaboration**
Heseltine, T; Murray, S; Brinksman, P; Fisher, M; McCarthy, G; Chaponda, M; Khoo, S (Liverpool, UK)*
- P066** **Examining associations between HIV status and high blood pressure (hypertension) in a high HIV prevalence population in Manicaland, east Zimbabwe: a cross-sectional study of adults**
Davis, K; Moorhouse, L; Maswera, R; Nyamukapa, C; Smit, M; Gregson, S (London, UK)*
- P067** **Comparing the prevalence of hypertension by HIV status in sub-Saharan African adults: a systematic review and meta-analyses of cross-sectional studies**
Davis, K; Perez Guzman, P; Gregson, S; Smit, M (London, UK)*
- P068** **The prevalence and risk factors for peripheral artery disease in chronic kidney disease in HIV-infected persons**
Viskovic, K; Marinelli, A; Nedeljko, K; Javoric, I; Bogdanic, N; Zekan, S; Begovac, J (Zagreb, Croatia)*
- P069** **Influence of CD4+/CD8+ ratio on early age of stroke in persons living with HIV: a single university centre study in Portugal**
Pais-de-Lacerda, A; Moreira, S; Simões Coelho, P (Lisboa, Portugal)*
- P070** **Left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients: prevalence and associations with clinical characteristics**
Basoulis, D; Athanasiadi, E; Bonou, M; Masoura, C; Skouloudi, M; Kapelios, C; Barbetseas, J; Psychogiou, M (Athens, Greece)*
- P071** **Transcranial Doppler pulsatility index as a marker of endothelial dysfunction, especially useful when before persistently low CD4+/CD8+ ratios**
Pais-de-Lacerda, A; Lira, A; Soares, F; Badura, R; Valadas, E; Simões Coelho, P; Oliveira, V (Lisboa, Portugal)*

Co-morbidities and Complications of Disease and/or Treatment: Malignancies

- O124** **The relationship between smoking, CD4, viral load and cancer risk in HIV-positive adults**
Mocroft, A; RESPOND (London, UK)*
- P072** **A 10-year case series of HHV8-related diseases in an ethnically diverse HIV cohort: is human herpesvirus 8 level a clue to the underlying pathology?**
Oliveira, A; Patel, N; Sanei, F; Sudhanva, M; Childs, K; Hamlyn, E (London, UK)*
- P073** **Results of HPV testing from three anatomical locations among men with different HIV status and sexual behaviour**
Popova, A; Domonova, E; Pokrovskaya, A; Shipulina, O; Pokrovskiy, V (Moscow, Russian Federation)*



Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Metabolic

- O111 Fat distribution and density in people living with HIV with $\geq 5\%$ weight gain**
Guaraldi, G; Draisci, S; Milic, J; Carli, F; Besutti, G; Bassoli, C; Raimondi, A; Ciusa, G; Ligabue, G; Mussini, C; Erlandson, K; Brown, T; Lake, J (Modena, Italy)*
- P074 NAFLD with significant fibrosis in people living with HIV informs the natural history of cardiovascular disease**
Milic, J; Cervo, A; Carli, F; Ciusa, G; Menozzi, M; Dolci, G; Bacca, E; Rogati, C; Tutone, M; Mazzola, G; Mussini, C; Sebastiani, G (Modena, Italy)*
- P075 Differential effects of raltegravir, dolutegravir and bictegravir on human adipocytes**
Domingo, P; Quesada-López, T; Villarroya, J; Gutierrez, M; Mur, I; Corbacho, N; Mateo, G; Domingo, J; Villarroya, F; Giral, M (Barcelona, Spain)*
- P076 Genetic markers of NAFLD associated with NASH in HIV-infected patients**
Busca, C; Sanchez-Conde, M; Arias, P; Rico, M; Montejano, R; Martin-Carbonero, L; Bernardino, J; Pérez-Valero, I; Valencia, E; Moreno, V; Mican, R; Oliveira, A; González-García, J; Montes-Ramirez, M (Madrid, Spain)*
- P077 Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide**
Lowman, E; Hardigan, P; Unger, N; Lee, N (Oakland Park, FL, USA)*
- P078 Hepatic fibrosis in people with HIV and non-alcoholic fatty liver disease: baseline data from an open-label, feasibility randomised trial of maraviroc plus optimised background therapy (OBT) versus OBT alone**
Bradshaw, D; Abramowicz, I; Bremner, S; Gilleece, Y; Fedele, S; Kirk, S; Clarke, C; Williams, S; Jennings, L; Scanlon, D; Lambert, P; Verma, S; Orkin, C; Nelson, M; Gompels, M; Fox, A; Clarke, E; Chadwick, D; Perry, N (Brighton, UK)*
- P079 The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: central nervous system penetration effectiveness (CPE) score evolution from baseline to 2-year follow-up**
Damas, J; Nadin, I; Calmy, A; Assal, F; Hauser, C; Hasse, B; Schlosser, L; Tarr, P; Stoeckle, M; Kunze, U; Schmid, P; Hundsberger, T; Di Benedetto, C; Rossi, E; Ledergerber, B; Du Pasquier, R; Darling, K; Cavassini, M (Lausanne, Switzerland)*

Co-morbidities and Complications of Disease and/or Treatment: Neurological

- P080 Clinical utility of β -amyloid PET imaging in people living with HIV with cognitive symptoms**
Vera, J; Eftychiou, N; Schuerer, M; Rullmann, M; Barthel, H; Sabri, O; Gisslen, M; Zetterberg, H; Blennow, K; O'Brien, C; Banerjee, S; Dizdarevic, S (Brighton, UK)*
- P081 CNS HIV viral escape syndrome presenting with persistent HIV viremia**
Schinold, M; Kogilwaimath, S; Fitzgerald, N; Pozniak, C (Saskatoon, Canada)*
- P082 Utility of Pittsburgh Sleep Quality Index (PSQI) in PLWH for assessment and monitoring of sleep disturbance in a community HIV clinic**
Gorney, B; Waddicar, A; Croston, M (Salford, UK)*



Scientific Posters

Co-morbidities and Complications of Disease and/or Treatment: Neurological (continued)

- P083** Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
*Tiraboschi, J**; Prieto, P; Saumoy, M; Silva, A; Imaz, A; Scevola, S; Fernandez-Olivares, G; Navarro-Alcaraz, A; Piatti, C; Podzamczar, D (L'Hospitalet, Barcelona, Spain)
- P084** Perception of Spanish HIV physicians towards diagnosis and management of neuropsychiatric comorbidities in people with HIV
*Pérez Valero, I**; Blanch Andreu, J; Martínez Chamorro, E (Madrid, Spain)

Co-morbidities and Complications of Disease and/or Treatment: Other

- P085** Important factors related to the sexual quality of life among men living with HIV/AIDS
*Etemadi, F**; Bessonneau, P; Huntingdon, B; Fofana Dara, A; Juraskova, I; Da Silva, M; Thomas, R; Griffi, J; Thonon, F; Chassany, O; Rodriguez, S; Duracinsky, M (Paris, France)
- P086** Meeting the fourth 90: evaluating the mental health of an urban population of people living with HIV in a Greater London clinic
*Mortimer, H**; Fowler-Williams, C; Dunin-Skrzynno, S; Cormack, I (London, UK)
- P087** Gastrointestinal (GI) adverse events with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) through Week 96: an EMERALD post-hoc analysis
*Dunn, K**; Baugh, B; Bejou, N; Luo, D; Campbell, J; Seyedkazemi, S (Titusville, NJ, USA)
- P088** Prevalence of HIV-related stigma among participants of the Swiss HIV Cohort Study: a pilot study
*Kampouri, E**; Damas, J; Jackson-Perry, D; Cobos Manuel, I; Scherrer, A; Cavassini, M; Darling, K (Lausanne, Switzerland)
- P089** The prevalence of major comorbidities among people living with HIV in Croatia
*Benkovic, I; Mocibob, L; Zekan, S; Lukas, D; Bogdanic, N; Begovac, J** (Zagreb, Croatia)
- P090** Frailty prevalence in people living with HIV from three HIV clinics in Lisbon
*Flor de Lima, B**; Silva, A; Pedro, D; Leitão, I; Pintado Maury, I; Caixeiro, M; Macedo, A (Amadora, Portugal)
- P091** Importance of screening for depression in people living with HIV in Ukraine
*Lopatina, Y; Momotyuk, G; Zakowicz, A**; Kalandia, H (Amsterdam, Netherlands)
- P092** Analysis of adherence to HIV-positive quality of care indicators and their impact on health-related quality of life: a Spanish cross-sectional study
*Gimeno-García, A**; Montero-Hernández, C; Franco-Moreno, A; Arponen, S; García-Carrasco, É; Corps-Fernández, D; Alejos, B; Varillas-Delgado, D; Galindo-Jara, P; García-Navarro, M (Torrejón de Ardoz, Spain)
- P093** Real-world characterisation of the Portuguese population living with HIV who initiated raltegravir-based regimen between 2015 and 2017 - REALITY study
*Serrão, R; Mansinho, K; Maltez, F; Marques, N; Carvalho, A; Pazos, R; Zagalo, A; Mendez, J; Neves, I; Oliveira, J; Pacheco, P; Correia de Abreu, R; Miranda, A**; Camacho, A; Paixão, L; Almeida, J (Lisboa, Portugal)



Scientific Posters

Viral Hepatitis

- P094** **Phylodynamics of sexually acquired HCV-3a in HIV co-infected patients in Hong Kong**
Kwan, T; Wong, B; Chan, D; Wong, N; Lee, S (Shatin, Hong Kong)*
- P095** **Efficacy, safety and convenience of integrase strand transfer inhibitors-based ART regimens in people living with HIV coinfecting with hepatitis C and/or B viruses**
Carosi, G; Rich, S; Prosperi, M; Mazzini, N; Nasta, P; Quiros Roldan, E; Di Filippo, E; Cauda, R; Saracino, A; Angarano, G; Vichi, F; Esperti, S; Sighinolfi, L; Segala, D; Lapdauila, G; Bonfanti, P; Fornabaio, C (Brescia, Italy)*
- P096** **Hepatitis C infection and treatment outcomes in the direct-acting antiviral era**
Jewsbury, S; Newton, P; Tomkins, A; Garner, A; Teo, S; Ahmad, S; Saxon, C; Ward, C; Prince, M; Lee, V (Manchester, UK)*
- P097** **Features of HIV and HCV epidemics in central part of Ukraine**
Koval, T; Marchenko, O; Sabinina, O; Koval, A (Poltava, Ukraine)*

Clinical Pharmacology

- P098** **Evaluation and clinical application of fostemsavir co-administration with tuberculosis medications**
Moore, K; Nguyen, D; Tai, G; Magee, M; Gorycki, P; Lee, T; Ackerman, P; Llamoso, C; Clark, A (Research Triangle Park, NC, USA)*
- P099** **Safety, tolerability, and pharmacokinetics following single- and multiple-dose administration of the novel NNRTI MK-8507 with a midazolam interaction arm**
Ankrom, W; Schaeffer, A; Panebianco, D; Friedman, E; Tomek, C; Stoch, A; Iwamoto, M (Kenilworth, NJ, USA)*
- P100** **The clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide - Real-world data from the German IQVIA prescription database**
Umland, T; Stellbrink, H; Calvo, M; Zahn, A (Hamburg, Germany)*
- P101** **Development and clinical validation of an liquid chromatography with ultraviolet detection method to quantify dolutegravir in dried blood spots**
Akinloye, A; Adeagbo, B; Bolaji, O; Olagunju, A (Ile-Ife, Nigeria)*
- P102** **Fostemsavir and ethinyl estradiol drug interaction: clinical application for coadministration**
Nwokolo, N; Post, E; Magee, M; Ackerman, P; Llamoso, C; Moore, K (Brentford, UK)*

Community Initiatives

- P103** **Awareness and perception of accuracy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA) in Italy and correlation with the level of confidence in reference physicians**
Cingolani, A; Tavelli, A; Calvino, G; Maggiolo, F; Girardi, E; Cozzi-Lepri, A; Perziano, A; Camposeragna, A; Gagliardini, R; Nozza, S; Antinori, A; d'Arminio Monforte, A (Rome, Italy)*



Scientific Posters

Community Initiatives (continued)

- P104** **What's trending in Asia? Drawing inferences from online HIV support seeking patterns of risk groups in Asia using regional Adam's Love and TemanTeman.org big datasets**
Anand, T; Nitpolprasert, C (Bangkok, Thailand)*
- P105** **HIV prevention among MSM in Japan: current opinions on achieving the first 90 among Japanese MSM**
Anand, T; Nitpolprasert, C; Shirasaka, T; Iwatani, Y; Yokomaku, Y; Imahashi, M; Kaneko, N; Iwahashi, K; Ikushima, Y; Aoki, R; Ishida, T; Shiono, S; Yamaguchi, M; Takemura, K; Iwamoto, A (Bangkok, Thailand)*
- P107** **Thinking outside the box: evaluating the impact of a virtual classroom model to deliver HIV primary care education to physicians and nurse practitioners across Saskatchewan, Canada**
Stewart, K; Kogilwaimath, S; Galambos, A (Saskatoon, Canada)*
- P109** **Sexual behaviours and associated factors among men living with HIV in Istanbul, Turkey**
Kumbasar Karaosmanoglu, H; Altuntas Aydin, O; Yesilbag, Z (Istanbul, Turkey)*
- P110** **Capacity building for youth coalitions, critical for sustaining gains in HIV prevention sphere**
Ita, D; Alaka, O; Durueke, F (Lagos, Nigeria)*

Models of Care: Cost Effectiveness and Evaluation of Delivery and Coverage

- P111** **EmERGE: feasibility and uptake of a co-designed digital health supported pathway of care for people living with medically stable HIV**
Whetham, J; Jones, C; Bremner, S; Apers, L; Begovac, J; Borges, M; Leon, A; Vera, J; Zekan, S; West, B; Chausa, P; Gomez, E; Garcia, F; EmERGE Consortium (Brighton, UK)*
- P112** **Differences in patient-reported outcomes among single- and multi-tablet regimens**
Degroote, S; Vanden Bulcke, C; Vogelaers, D; Vandekerckhove, L (Ghent, Belgium)*
- P113** **Community responses on variability in the frequency of patient visits to HIV clinics in the EU**
Greenhalgh, F; West, B; Von Lingen, A; Dutarte, M; Whetham, J (Edinburgh, UK)*
- P114** **Modelling the future of HIV in Turkey: disease implications of improving prevention, diagnosis and treatment**
Yaylali, E; Gökengin, D; Korten, V; Tabak, F; Ünal, S; Erdogan, Z; Çalıřır, F; Özelgün, B; Şahin, T (Istanbul, Turkey)*
- P115** **To 90-90-90 and beyond: feasibility and clinical outcomes of same-day ART initiation among PLHIV in a real-life, middle-income setting**
Barletta, J; Jaume, M; De Ilzarbe, M; Bruno, D; Romero, A; Tokumoto, N; Vigo, G; Díaz, L; Cando, O; Rolón, M (Buenos Aires, Argentina)*
- P116** **Community responses about access to and importance of telemedicine by PLHIV and clinical staff in the EU**
Greenhalgh, F; West, B; Von Lingen, A; Dutarte, M; Whetham, J (Edinburgh, UK)*
- P117** **Ensuring continuity of care for people living with HIV in five European countries: the efficiency of the EmERGE platform**
Beck, E; Mandalia, S; Yfantopoulos, P; Leon, A; Merino, M; Garcia, F; Wittevrongel, M; Apers, L; Benkovic, I; Zekan, S; Begovac, J; Cunha, A; Teofilo, E; Rodrigues, G; Borges, M; Fatz, D; Vera, J; Whetham, J (London, UK)*



Scientific Posters

Models of Care: Cost Effectiveness and Evaluation of Delivery and Coverage (continued)

- P118 To 90-90-90 and beyond: a community-focused multimodal, interdisciplinary intervention to optimise continuum of care among recently diagnosed PLHIV in a middle-income setting**
*De Ilzarbe, M**; Bruno, D; Jaume, M; Barletta, J; Romero, A; Tokumoto, N; Vigo, G; Díaz, L; Cando, O; Rolón, M (Buenos Aires, Argentina)
- P119 Comprehensive retention to care model: results of the pilot in Krasnoyarsk, Russia 2016-2019**
*Kandlen, K**; Chuykov, A; Boiko, A; Burdina, Y; Zakowicz, A; Mironova, N (Saint Petersburg, Russian Federation)

Virology and Immunology

- O323 Impact of multi-drug resistance on mortality: a multi-cohort Italian study**
*Gagliardini, R**; Cozzi-Lepri, A; Zazzi, M; Tavelli, A; Santoro, M; Armenia, D; Castagna, A; Gennari, W; Rusconi, S; Mussini, C; Laghetti, P; Perno, C; D'Arminio Monforte, A; Antinori, A (Rome, Italy)
- O324 Lenacapavir resistance analysis in a phase Ib clinical proof-of-concept study**
*Margot, N**; Ram, R; Parvanga, P; Martin, R; Hyland, R; Rhee, M; Callebaut, C (Foster City, CA, USA)
- O443 Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults infected with HIV: a phase III trial**
*Mohapi, L; Osiyemi, O**; Supparatpinyo, K; Ratanasuwan, W; Molina, J; Dagan, R; Tamms, G; Sterling, T; Zhang, Y; Hartzel, J; Pedley, A; Kan, Y; Hurtado, K; Buchwald, U; Musey, L; Simon, J (West Palm Beach, FL, USA)
- P120 Islatravir selects for HIV-1 variants in MT4-GFP cells that profoundly reduce replicative capacity in peripheral blood mononuclear cells**
*Diamond, T**; Ngo, W; Xu, M; Goh, S; Rodriguez, S; Lai, M; Asante-Appiah, E; Grobler, J (Kenilworth, NJ, USA)
- P121 Impact of resistance to antiretroviral drugs on predicted HIV-1 susceptibility to current single-tablet regimens (STRs)**
*Rossetti, B**; Di Carlo, D; Fabbiani, M; Stella, G; Vicenti, I; Maggiolo, F; Gennari, W; Francisci, D; Santoro, M; Zazzi, M (Siena, Italy)
- P122 Impact of genetic variation of the APOBEC3G gene on HIV RNA, T-cell counts, markers of inflammation and clinical events**
*Domínguez-Domínguez, L**; Reekie, J; Leung, P; Zucco, A; Novak, R; Gilson, R; Stephan, C; Rupasinghe, D; Helleberg, M; MacPherson, C; Lundgren, J; Murray, D; INSIGHT START Study Group (Copenhagen, Denmark)
- P123 Sustained viral suppression after switch to bicitgravir/emtricitabine/tenofovir alafenamide among clinical trial participants with preexisting M184V/I**
*Andreatta, K**; Acosta, R; D'Antoni, M; Porter, D; Chang, S; Martin, R; Willkom, M; McNicholl, I; Gallant, J; Pikora, C; Graham, H; Collins, S; Martin, H; White, K (Foster City, CA, USA)
- P124 Bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F**
*Acosta, R**; Andreatta, K; D'Antoni, M; Collins, S; Martin, H; White, K (Foster City, CA, USA)
- P125 Development of integrase inhibitor resistance under first-line treatment with bicitgravir**
*Stoll, M; Braun, P**; Wiesmann, F; Knechten, H (Aachen, Germany)



Scientific Posters

Virology and Immunology (continued)

- P126 Barriers for participation in HIV vaccine trials among general population in Argentina: first interim survey**
Cecchini, D;* Ballivian, J; Feld, D; Cassetti, I (Buenos Aires, Argentina)

Late Presenters

- P127 Improving the HIV testing cascade: adequate identification of patients with HIV indicator conditions in hospitals by electronic registration systems**
Jordans, C;* Hensley, K; Vogel, M; van Kampen, J; Boucher, C; Mollema, F; Gisolf, J; El Moussaoui, R; Hermanides, G; van der Valk, M; Finkenflügel, R; Rijnders, B; Verbon, A; Rokx, C (Rotterdam, Netherlands)
- P128 Routine, automated and clinician independent universal screening of HIV infection in an emergency department: reducing late presentation by overcoming barriers to testing**
Vaz Pinto, I;* Guimaraes, M; Castro, V; Santos, C; Galiano, A; Friaes, J; Bilé, A (Alcabideche, Portugal)
- P129 Effectiveness and persistence of F/TAF-containing regimens (E/C/F/TAF, R/F/TAF or F/TAF+3rd in late and very late presenters: final 24-month results from the German TAFNES cohort study**
Postel, N;* Jessen, H; Pauli, R; Hillenbrand, H; Heuchel, T; Rieke, A; Knechten, H; Emmerich, C; Schreiber, S; Mack, F; Haubrich, R; Stellbrink, H (Munich, Germany)
- P130 Late presenters of HIV infection during COVID-19 pandemic**
Panagopoulos, P; Petrakis, V*; *Kyrgiannaki, V; Kriaraki, Z; Papazoglou, D (Alexandroupolis, Greece)*

COVID-19

- O242 STI and HIV testing to break the chain of infection: local innovation in the midst of COVID-19**
Wood, C;* Ahmad, S; Jewsbury, S; Redmond, M; Saxon, C; Sukthankar, A; Thomas, D; Ward, C; McQuillan, O (Manchester, UK)
- O422 Outcomes of COVID-19 related hospitalisation among people with HIV in the United Kingdom and comparison to those without HIV**
Geretti, A;* Stockdale, A; Kelly, S; Villa, G; Turtle, L; Semple, M; Sabin, C (Liverpool, UK)
- O444 SARS-CoV-2 infection in pregnancy and newborn in a Spanish multicentric cohort (GESNEO-COVID)**
Carrasco, I;* Muñoz, M; Vigil, S; Aguilera, D; Riaza, M; Sanz, O; Pareja, M; Baña, A; Sanchez Luna, M; Navarro, M (Madrid, Spain)
- P131 Resilience and frailty in people living with HIV during the lockdown experience in Italy in March-May 2020: are they two complementary constructs?**
Guaraldi, G;* Milic, J; Ciusa, G; Raimondi, A; Cuomo, G; Carli, F; Mussini, C (Modena, Italy)
- P132 Impact of COVID pandemic among men who have sex with men living with HIV during COVID lockdown in Argentina**
Ballivian, J;* Cecchini, D; Alcaide, M; Abbamonte, J; Jones, D; Cassetti, I (Buenos Aires, Argentina)
- P133 COVIDApp: a health application as an innovative strategy for the management of the COVID-19 pandemic in long-term care facilities**
Echeverría, P;* Mas, M; Puig, J; Isnard, M; Massot, M; Vedia, C; Peiró, R; Ordorica, Y; Pablo, S; Ulldemolins, M; Iruela, M; Balart, D; Ruiz, J; Herms, J; Clotet, B; Negro, E (Barcelona, Spain)



Scientific Posters

COVID-19 (continued)

- P134 SARS-CoV2 pandemic: SARS-CoV2 seroprevalence and impact on HIV suppression in PLWH**
Cuomo, G; Bacca, E; Menozzi, M; Carli, F; Borghi, V; Guaraldi, G; Mussini, C (Modena, Italy)*
- P135 Prevalence of respiratory virus infections during a SARS-CoV2 epidemic**
Sukach, M; Ingiliz, P; Valin, N; Boussaid, K; Julienn, J; Chiarabini, T; Morand-Joubert, L; Gozlan, J; Schnuriger, A; Lacombe, K (Paris, France)*
- P136 Prophylactic dose of low-molecular-weight heparin (LMWH) might not be sufficient to mitigate the clinical scenario in patients with COVID-19 and severe pneumonia**
Vergori, A; Donno, D; Lorenzini, P; Nicastrì, E; Gualano, G; Iacomì, F; Marchioni, L; Schininà, V; Cicalini, S; Agrati, C; Capobianchi, M; Girardi, E; Ippolito, G; Vaia, F; Petrosillo, N; Antinori, A; Taglietti, F (Rome, Italy)*
- P137 Symptoms of viral infection and polymerase chain reaction (PCR) positivity rates of SARS-CoV2 in healthcare professionals in Paris, France**
Sukach, M; Ingiliz, P; Valin, N; Barbut, F; Morand-Joubert, L; Gozlan, J; Schnuriger, A; Lacombe, K (Paris, France)*
- P138 Understanding how HIV testing has been affected by the COVID-19 response**
Greenhalgh, F; Von Lingen, A; Cigan, B; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)*
- P139 Cross-border movement restrictions during Covid-19 and foreign nationals' access to healthcare and medicines**
Greenhalgh, F; Von Lingen, A; Cigan, B; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)*
- P140 The impact of COVID-19 epidemic on HIV care in Croatia**
Bogdanic, N; Zekan, S; Romih Pintar, V; Lukas, D; Begovac, J (Zagreb, Croatia)*
- P141 Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago**
Sherer, R; Lehmann, C; Zhu, M; Lio, J (Chicago, IL, USA)*
- P142 Effect of first 3 months of COVID pandemic on HIV services in Greece: a short survey among HIV physicians**
Lourida, G; Leonidou, L; Psychogiou, M; Chrysanthidis, T; Protopappas, K; Katsarolis, I; Xylomenos, G; Panagopoulos, P; Chini, M; Papastamopoulos, V (Athens, Greece)*
- P143 Fears and perception of the risk of infection with SARS-CoV-2 in a cohort of HIV+ subjects on antiretroviral treatment in an outpatient clinic in Sicily**
Ceccarelli, M; Marino, A; Accordino, S; Lupo, G; Boscia, V; Cosentino, F; Moscatt, V; Bruno, R; Pampaloni, A; Scuderi, D; Cacopardo, B; Celesia, B (Catania, Italy)*
- P144 How has the COVID-19 response changed medicine deliveries for people living with or at risk of HIV?**
Greenhalgh, F; Von Lingen, A; Cigan, B; Varasi, P; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)*



Scientific Posters

COVID-19 (continued)

- P145** **Characterisation of PLWH with COVID-19 in a tertiary care reference centre for emerging infectious diseases in Portugal**
Nunes Silva, C; Caldas, J; Martins, A; Policarpo, S; Rocha, R; Freitas, F; Mesquita, M; Abreu, I; Graça, L; Palma Martins, P; Ceia, F; Pineiro, C; Neves, N; Silva, S; Tavares, M; Serrão, R; Sarmiento, A (Porto, Portugal)*
- P146** **Assessing the mental health of people living with HIV in Scotland during COVID-19**
Hirono, J; Sparling, N (Edinburgh, UK)*
- P147** **Characteristics and outcomes of inpatient COVID-19 infections in people living with HIV**
Jewsbury, S; Garner, A; Houston, J; Polden, M; Saxon, C; Tomkins, A; Lee, V (Manchester, UK)*
- P148** **SARS-CoV-2 infection in HIV patients: we anticipated a worse scenario**
Bastos, L; Pocinho, S; Machado, A; Guerreiro, G; Domingos, J; Miranda, C; Goncalves, E; Fonseca, C; Mansinho, K (Lisboa, Portugal)*
- P149** **Understanding how the COVID-19 response affects the quality of care services for people living with HIV and communities affected by HIV**
Greenhalgh, F; Von Lingen, A; Cigan, B; Barbareschi, G; Amort, F; Cascio, M; Schneider, A; Hodgson, I (Brussels, Belgium)*